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Abstract
Background: To evaluate the performance of three different advanced treatment techniques on
a group of complex paediatric cancer cases.
Methods: CT images and volumes of interest of five patients were used to design plans for Helical
Tomotherapy (HT), RapidArc (RA) and Intensity Modulated Proton therapy (IMP). The tumour
types were: extraosseous, intrathoracic Ewing Sarcoma; mediastinal Rhabdomyosarcoma;
metastastis of base of skull with bone, para-nasal and left eye infiltration from Nephroblastoma of
right kidney; metastatic Rhabdomyosarcoma of the anus; Wilm's tumour of the left kidney with
multiple liver metastases. Cases were selected for their complexity regardless the treatment intent
and stage. Prescribed doses ranged from 18 to 53.2 Gy, with four cases planned using a
Simultaneous Integrated Boost strategy. Results were analysed in terms of dose distributions and
dose volume histograms.
Results: For all patients, IMP plans lead to superior sparing of organs at risk and normal healthy
tissue, where in particular the integral dose is halved with respect to photon techniques. In terms
of conformity and of spillage of high doses outside targets (external index (EI)), all three techniques
were comparable; CI90%  ranged from 1.0 to 2.3 and EI from 0 to 5%. Concerning target
homogeneity, IMP showed a variance (D5%–D95%) measured on the inner target volume (highest
dose prescription) ranging from 5.9 to 13.3%, RA from 5.3 to 11.8%, and HT from 4.0 to 12.2%.
The range of minimum significant dose to the same target was: (72.2%, 89.9%) for IMP, (86.7%,
94.1%) for RA, and (79.4%, 94.8%) for HT. Similarly, for maximum significant doses: (103.8%,
109.4%) for IMP, (103.2%, 107.4%) for RA, and (102.4%, 117.2%) for HT. Treatment times (beam-
on time) ranged from 123 to 129 s for RA and from 146 to 387 s for HT.
Conclusion: Five complex pediatric cases were selected as representative examples to compare
three advanced radiation delivery techniques. While differences were noted in the metrics
examined, all three techniques provided satisfactory conformal avoidance and conformation.
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Background
Approximately fifty percent of paediatric cancer patients
receive radiotherapy as part of their oncologic manage-
ment [1]. In this population, balancing the potential for
early and late toxicity against tumour control is particu-
larly important. IMRT has been shown in several instances
to improve conformal avoidance when compared to 3D
conformal techniques and its role was investigated in a
previous study on the same group of patients [2] and by
many other authors [3-9]. Despite its potential, advanced
photon treatments (mostly with IMRT) are still not widely
used in the paediatric field as there is a substantial lack of
knowledge on the late side effects [5]. The availability of
more sophisticated techniques like intensity-modulated
protons, helical tomotherapy and the newly introduced
RapidArc, triggered interest in performing a new investiga-
tion to compare relevant dosimetric metrics when applied
to paediatric cases.
Several pilot studies have studied the use of protons in
paediatric radiation oncology [10-14] for various disease
sites. In all cases a significant potential in terms of sparing
of organs at risk, reduction of healthy tissue involvement
and reduction of risk for secondary cancer induction was
demonstrated. In comparing helical tomotherapy (HT)
with other advanced photon delivery for cranial-spinal
and extra-cranial irradiation, HT showed a superior degree
of conformality [15-17]. Tempering these benefits, is the
secondary neutron production by some proton tech-
niques (passive scattering) and increased low dose radi-
ated volumes for intensity modulated photon techniques
that could contribute to an increase in second malignan-
cies. Hall [18,19] suggested that children are more sensi-
tive than adults by a factor of 10; in addition, there is an
increased genetic susceptibility of paediatric tissues to
radiation-induced cancer. Conversely, a recent publica-
tion from Schneider et al [20], estimating the relative
cumulative risk in child and adult for IMRT and proton
treatment with respect to conformal therapy, concludes
that in the child, the risk remains practically the same for
the two photon techniques or is reduced when proton
therapy is used. This fact strengthen the interest in investi-
gating new photon modalities in children cancer care.
In paediatric oncology, the variety of indications is large
and, at the limit, every individual patient presents peculi-
arities preventing easy generalisations. As done in the pre-
vious investigation on IMRT [2], rather than selecting one
single pathology and a consistent cohort of patients, we
selected a small group of highly complex cases, presenting
specific planning challenges regardless from the treatment
intent and the actual stage of the diseases. The present
study aims to address the problem of new technical solu-
tions in paediatric radiation oncology: assuming that
research activity in treatment planning, and not only at
clinical level, should be promoted, it is important to ana-
lyse if the available tools could be adequate and effective
also for those patients. Clinical potentials and outcomes
should be addressed in clinical trials, and are not subject
of comparative planning studies.
In the present paper a comparison among three highly
sophisticated techniques has been carried out. No data
have been reported here comparing IMRT, provided
already in the previous publication [2] on the same group
of patients, where different treatment planning systems
where used; in that report, a conventional regime was
used, but results would not substantially change on dosi-
metric comparison. In addition, comparison of also nor-
mal 3D-CRT (and IMRT) is not in the scope of this work
because complex paediatric cases are not ideally planned
with conventional approaches, while a clear preference is
given to protons; RapidArc and Helical Tomotherapy
could constitute and interesting intermediate level of
standard, and aim of the present investigation is to under-
stand their role with respect to the ideal solution of pro-
tons.
Methods and patients
Five paediatric patients, affected by different types of can-
cer in different, challenging anatomic configurations were
selected. The choice aimed to identify a group of difficult
and challenging indications in terms of tumour location,
anatomical boundary conditions, dose coverage, toler-
ance requirements. These cases might be also technical
paradigm for other clinical indications with similar chal-
lenges.
A detailed summary of the indications, volume sizes, dose
prescriptions and planning objectives is outlined in table
1. For all cases, except patient 5, the treatment was struc-
tured on two volumes to be concurrently irradiated by
means of Simultaneous Integrated Boost approach: PTV1
being in general the elective and PTV2 the boost volumes.
For patient 1 the boost volume was the surgical scar, not
included in the elective volume and receiving a lower
dose, while in patient 4 the boost volume excluded the
inguinal nodes. The objectives concerning OARs refer
mainly to the report of the National Cancer Institute
[21,22]. Dose was normalised to the mean dose of the
PTV volume receiving the higher dose prescription. The
three following objectives were specified: i) target cover-
age (min. dose 90%, max. dose 107%), ii) OAR sparing to
at least the limits stated in table 1, iii) sparing of Healthy
Tissue (defined as the CT dataset patient volume minus
the volume of the largest target).
The cases were selected in order to obtain a minimal set of
complicated planning situations with specific challenges
as described in [2] and summarized as follows:Radiation Oncology 2009, 4:2 http://www.ro-journal.com/content/4/1/2
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For patient 1, the target was adjacent to the spinal cord,
partially inside the lung with a long scar (about 5 cm) gen-
erating a secondary target volume, separated from the
main one (smaller in volume) located along the thoracic
wall and requiring simultaneous boost.
For patient 2, the location of the target in the mediasti-
num would be relevant in terms of large dose baths in the
lung (and eventually breast) regions.
For patient 3, sparing of the right eye (the only functional)
was the primary planning issue.
For patient 4, the target volume was divided into three
separate regions (the anal volume and the two inguinal
node regions) with organs at risk (uterus, bladder and rec-
tum) generally positioned between the three targets.
For patient 5, the target volume was given by the entire
liver and the main organ at risk was the right kidney with
a low tolerance, located proximal/adjacent to the target.
The sparing of this kidney had a very high priority since
the patient underwent left nephrectomy.
Planning techniques
RapidArc (RA)
RapidArc uses continuous variation of the instantaneous
dose rate (DR), MLC leaf positions and gantry rotational
speed to optimise the dose distribution. Details about
RapidArc optimisation process have been published else-
where by our group [23,24]. To minimise the contribu-
tion of tongue and groove effect during the arc rotation
and to benefit from leaves trajectories non-coplanar with
respect to patient's axis, the collimator rotation in Rapi-
dArc remains fixed to a value different from zero (from 20
Table 1: Main characteristics of patients and treatment plan.
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Patient Male, 12 y.o. Female, 8 y.o. Female, 5 y.o. Female, 13 y.o. Female, 8 y.o.
Diagnosis Ewing Sarcoma 
extraosseous, 
intrathoracic
Rhabdomyosarcoma 
mediastinum, stage III
Metastasis of base of 
skull with bone, para-
nasal and lef eye 
infiltration from 
Nefroblastoma of 
right kidney
Rhabdomyosarcoma 
anus.
Metastasis 
lymphnodes 
intrapelvic, inguinal 
and osseous
Wilm's tumour of the 
left kidney.
(Multiple lung 
metastasis).
Multiple liver 
metastasis
Status After chemotherapy + 
surgery + 
chemotherapy
After chemotherapy After chemotherapy + 
right nefrectomy
After chemotherapy After chemotherapy + 
left nefrectomy + 
chemo-radiotherapy 
for lung metastasis
Radiotherapy dose
Prescription
PTV = 28 × 1.9 = 53.2 
Gy
PTV scar = 28 × 1.6 = 
44.8 Gy
PTVII = 25 × 1.98 = 
49.5 Gy
PTVI = 25 × 1.80 = 
45.0 Gy
PTVII = 17 × 2.5 = 
42.5 Gy
PTVI = 17 × 1.8 = 
30.6 Gy
PTVII = 25 × 1.98 = 
49.5 Gy
PTVI = 25 × 1.80 = 45 
Gy
PTV = 15 × 1.2 18 Gy
Target volumes PTV = 564 cm3
PTV scar = 14 cm3
PTVI = 109 cm3
PTVII = 72 cm3
PTVI = 1436 cm3
PTVII = 104 cm3
PTVI = 618 cm3
PTVII = 193 cm3
PTV = 1234 cm3
Organs at risk dose 
objectives
Lung1 < 15 Gy
Heart1 < 30 Gy
Vertebra1 < 20 Gy
Spinal cord2 < 45 Gy
Lung1 < 15 Gy
Heart1 < 30 Gy
Vertebra1 < 20 Gy
Spinal cord2 < 45 Gy
Right eye1 < 40 Gy
Left eye (blind)1 < 50 
Gy
Lens1 < 10 Gy
Spinal cord2 < 45 Gy
Rectum1 < 40 Gy
Bladder1 < 30 Gy
Uterus1 < 20 Gy
Femural heads1 < 20 
Gy
Kidney1 < 10 Gy
Techniques RA: 2 copl arcs, 
HDMLC
HT: Fld s. 2.5 cm, 
pitch 0.43
IMP: 3 fields
RA: 2 copl arcs, 
HDMLC
HT: Fld s. 2.5 cm, 
pitch 0.43
IMP: 2 fields
RA: 2 copl arcs, 
MLC120
HT: Fld s. 2.5 cm, 
pitch 0.43
IMP: 2 fields
RA: 2 non copl arcs, 
MLC120
HT: Fld s. 2.5 cm, 
pitch 0.43
IMP: 6 fields
RA: 2 non copl arcs, 
MLC120
HT: Fld s. 2.5 cm, 
pitch 0.43
IMP: 2 fields
Delivery time
MU
RA: 129 s, MU: 479
HT: 387 s MU: NA
IMP: NA MU: NA
RA: 123 s MU: 370
HT: 146 s MU: NA
IMP: NA MU: NA
RA: 129 s MU: 538
HT: 341 s MU: NA
IMP: NA MU: NA
RA: 127 s MU: 527
HT: 334 s MU: NA
IMP: NA MU: NA
RA: 129 s MU: 483
HT: 255 s MU: NA
IMP: NA MU: NA
1: mean dose; 2: maximum doseRadiation Oncology 2009, 4:2 http://www.ro-journal.com/content/4/1/2
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to 45 degrees in the present study). This technicality per-
mits to smear out the effect not having the interleaf space
on the same axial position through the whole arc, that
would transfer directly on the patient the tongue and
groove effect.
All plans were optimised on the Varian Eclipse treatment
planning system (TPS) (version 8.6.10) for a 6 MV photon
beam from a Varian Clinac. The MLC used were either a
Millennium with 120 leaves (spatial resolution of 5 mm
at isocentre for the central 20 cm and of 10 mm in the
outer 2 × 10 cm) or a High Definition (2.5 mm leaf width
at isocentre in the central 8 cm region and 5 mm in the 2
× 7 cm outer region), depending on the target size
(smaller volumes could benefit from High Definition
MLC). Two arcs were applied, either coplanar or non
coplanar. Details are reported in table 1. The Anisotropic
Analytical Algorithm (AAA) photon dose calculation algo-
rithm was used for all cases [25,26]. The dose calculation
grid was set to 2.5 mm.
Helical Tomotherapy (HT)
During HT treatment, a 6 MV x-ray fan beam intensity-
modulated by a binary multi-leaf collimator (MLC) is
delivered from a rotating gantry while a patient is slowly
moving through the gantry aperture resulting in a helical
beam trajectory. A collimator aperture of 25 mm and a
pitch of 0.43 were used for this study. The MLC is
equipped with 64 leaves with a 0.625 cm width at isocen-
tre. The gantry rotates at a constant speed while MLC
leaves open 51 times per rotation and close entirely
between different "projections". Plans were optimised
using an inverse treatment planning process (based on
least squares optimisation) determining MLC aperture
times and the dose is calculated using a superposition/
convolution approach. The software version used for this
study was HiART TomoPlan 1.2 (Tomotherapy Inc., Mad-
ison, US). Details on the HT optimisation process can be
found in [27,28]. Dose calculations were performed using
the fine dose calculation grid (3 mm in cranio-caudal
direction and over a 256 × 256 matrix in axial plane from
the original CT scan, i.e. approximately 2 × 2 mm2)
Intensity Modulated Protons (IMP)
Intensity modulated proton plans were obtained for a
generic proton beam through a spot scanning optimisa-
tion technique implemented in the Eclipse treatment
planning system from Varian [29,30]. The simultaneous
optimisation of the weight of each individual spot (from
any number of fields) is performed inside a point cloud
describing organs at risk and targets. Initial spot list is
obtained at a pre-processing phase. In this phase, energy
layers are determined which contain sets of spots located
inside the target (plus eventual margins). Weight optimi-
sation is performed starting from a dose deposition coef-
ficient matrix calculated as the dose that would be
deposited to each of the cloud points when irradiating
each single spot of the initial list with a unit intensity. At
the end of optimisation, a post-processing phase allows to
prune unused energy layers as well as unused spots. The
proton dose calculation algorithm used for the study was
the version 8.2.22. The maximum energy available was
250 MeV with an energy spacing of 10 MeV between the
layers. Applied nominal maximum energies ranged from
104 MeV (patients 2 and 4) to 152 MeV (patient 5). Spot
spacing was set to 3 mm, circular lateral target margins
were set to 5 mm, proximal margin to 5 mm and distal
margin to 2 mm. Dose calculation grid was 2.5 mm. ln all
cases coplanar beam arrangement was adopted using
from 2 to 6 fields as specified in table 1.
Evaluation tools
All dose distributions were generated or imported (via
DICOM) in the same treatment planning system
(Eclipse), and from that the Dose-Volume Histogram
(DVH) were exported to have all analysis based on DVH
obtained with the same sampling algorithm.
Evaluation of plans was performed by means of standard
DVH. For PTV, the values of D99% and D1% (dose received
by the 99%, and 1% of the volume) were defined as met-
rics for minimum and maximum doses. To complement
the appraisal of minimum and maximum dose, V90%,
V95%V107% and V110% (the volume receiving at least 90% or
95% or at most 107% or 110% of the prescribed dose)
were reported. The homogeneity of the treatment was
expressed in terms of the standard deviation (SD) and of
D5%–D95% difference. The conformality of the plans was
measured with a Conformity Index, CI90% defined as the
ratio between the patient volume receiving at least 90% of
the prescribed dose and the volume of the PTV. To
account for hot spots, the External volume Index (EID)
was defined as VD/VPTV where VPTV is the volume of the
envelope of PTV's and VD is the volume of healthy tissue
receiving more than the prescription dose. For OARs, the
analysis included the mean dose, the maximum dose
expressed as D1% and a set of appropriate VX and DY val-
ues. For healthy tissue, the integral dose, "DoseInt", is
defined as the integral of the absorbed dose extended over
all voxels but excluding those within the target volume
(DoseInt dimension is Gy*cm3). This was reported
together with the observed mean dose and some repre-
sentative Vx values.
To visualise the difference between techniques, cumula-
tive DVHs for PTV, OARs and healthy tissue, were
reported with a dose binning of 0.05 Gy.
For RA and HT, delivery duration was reported in terms of
beam-on time. Delivery time for IMP plans are notRadiation Oncology 2009, 4:2 http://www.ro-journal.com/content/4/1/2
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reported since the calculation model used in the study is
not tailored to any specific treatment facility. Relevant
technical parameters affecting delivery time (e.g. energy
switch systems, magnetic deflectors, couch movements)
cannot be simply generalised and could induce huge var-
iations in actual beam on times.
Results
Figures 1 to 5 present the dose distributions for our five
patients for the three techniques. In each figure, axial,
coronal, and sagittal views are shown to better appraise
general characteristics of dose distributions (e.g target
conformality and dose bath). The thresholds for the col-
our-wash representations are shown in the figures.
Figures 6 to 10 show the DVHs of various target volumes,
organs at risk and healthy tissue.
Tables 2 to 6 present a summary of the quantitative anal-
ysis performed on DVHs.
Table 7 present the average over the five patients of the
findings for the various target volumes and healthy tissue.
Target coverage
From table 7, within the limits of averaging over patients
with different characteristics, it can be seen that, for the
PTV at highest dose prescription, RA presents slightly bet-
ter D1%, D99%, V90%, V107%, V110%, SD; HT presents better
V95 and D5%–D95%, and IMP presents lowest CI90%. The
worst results for minimum dose and target coverage are
typically observed for IMP due to the limits imposed in
the optimisation phase to reduce at maximum high dose
levels around the target and to reach high conformality.
Concerning the outer target volumes PTVI-PTVII at lower
dose prescription (corresponding to PTV scar in the first
patient and PTVI left and right for patient 4) similar trends
can be observed with RA showing best findings for D1%,
D99%, V90%, V107%; HT for V95%, D5%–D95% and SD; IMP
only for V110%. All techniques, if considered from a clini-
cal perspective appear to be equivalent with a target cov-
erage at V90% superior to 98% for the high dose volumes
and to 92% for the low dose volumes, a heterogeneity
Dose distributions in axial coronal and sagittal views for RA, HT and IMPT for Patient 1 Figure 1
Dose distributions in axial coronal and sagittal views for RA, HT and IMPT for Patient 1.Radiation Oncology 2009, 4:2 http://www.ro-journal.com/content/4/1/2
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(D5%–D95%) lower to 9% on the high dose volumes and a
Dose distributions in axial coronal and sagittal views for RA, HT and IMPT for Patient 2 Figure 2
Dose distributions in axial coronal and sagittal views for RA, HT and IMPT for Patient 2.
Dose distributions in axial coronal and sagittal views for RA, HT and IMPT for Patient 3 Figure 3
Dose distributions in axial coronal and sagittal views for RA, HT and IMPT for Patient 3.Radiation Oncology 2009, 4:2 http://www.ro-journal.com/content/4/1/2
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conformity index inferior to 1.3.
Dose distributions in axial coronal and sagittal views for RA, HT and IMPT for Patient 4 Figure 4
Dose distributions in axial coronal and sagittal views for RA, HT and IMPT for Patient 4.
Dose distributions in axial coronal and sagittal views for RA, HT and IMPT for Patient 5 Figure 5
Dose distributions in axial coronal and sagittal views for RA, HT and IMPT for Patient 5.Radiation Oncology 2009, 4:2 http://www.ro-journal.com/content/4/1/2
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Dose-Volume Histograms for targets and organs at risk for Patient 1 Figure 6
Dose-Volume Histograms for targets and organs at risk for Patient 1.Radiation Oncology 2009, 4:2 http://www.ro-journal.com/content/4/1/2
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Dose-Volume Histograms for targets and organs at risk for Patient 2 Figure 7
Dose-Volume Histograms for targets and organs at risk for Patient 2.Radiation Oncology 2009, 4:2 http://www.ro-journal.com/content/4/1/2
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Dose-Volume Histograms for targets and organs at risk for Patient 3 Figure 8
Dose-Volume Histograms for targets and organs at risk for Patient 3.Radiation Oncology 2009, 4:2 http://www.ro-journal.com/content/4/1/2
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Dose-Volume Histograms for targets and organs at risk for Patient 4 Figure 9
Dose-Volume Histograms for targets and organs at risk for Patient 4.
Organs at risk
The different characteristics of patients prevent the possi-
bility to draw average conclusions and therefore the anal-
ysis was done separate for the five cases.
Patient 1
All techniques respected the objectives on the spinal cord,
heart and right lung. RA slightly failed to reach the plan-
ning objective for the vertebra and the uninvolved left
lung. The latter is likely due to the lateral spread of doses
in the low density medium physically not avoidable for
photon beams of 6 MV and differently modelled by the
convolution/superposition algorithms implemented in
Eclipse and TomoPlan. It is unlikely that optimisation
algorithm or hardware features of RA would be responsi-
ble of the effect that is not present in any other of the five
cases (where mostly water equivalent tissues are present).
Protons presented a significantly superior sparing of all
OARs as clearly shown in the DVH figure. RA and HT are
equivalent for the right lung and spinal cord; RA is mod-
erately superior to HT for heart while HT better spares the
left uninvolved lung.
Patient 2
All techniques respected planning objectives for this case.
Compared to HT, RA showed a lower involvement of both
lungs for doses below 20 Gy and a significantly lower
involvement of heart at all dose levels (e.g 10.5%
improvement for V20 Gy). HT is preferable for sparing the
vertebra for doses higher than 10 Gy while RA is better
below that level. No differences were observed for the spi-
nal cord.Radiation Oncology 2009, 4:2 http://www.ro-journal.com/content/4/1/2
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Dose-Volume Histograms for target and organs at risk for Patient 5 Figure 10
Dose-Volume Histograms for target and organs at risk for Patient 5.Radiation Oncology 2009, 4:2 http://www.ro-journal.com/content/4/1/2
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Patient 3
All techniques easily respected constraints on spinal cord
and right lens. HT slightly violated the objective on the
right eye. Figure 3 reports results also for the left eye
(blind) that are of no clinical relevance but interesting to
observe left-right "symmetry" of the different techniques.
Table 2: Results from dose plan analysis for Patient 1
Obj HT IMP RA
PTV
Mean [Gy] 53.2 53.2
(100%)
53.2
(100%)
53.2
(100%)
D1% [%] - 102.3 107.1 104.9
D99% [%] - 85.0 86.8 90.6
V90% [%] 100% 97.7 97.8 99.3
V95% [%] 100% 93.9 93.5 92.5
V107% [%] 0% 0.0 1.1 0.0
V110% [%] 0% 0.0 0.2 0.0
D5–D95 [%] - 8.1 10.9 10.0
SD [%] - 3.2 3.6 3.0
CI90 1.0 1.2 1.1 1.2
PTV scar
Mean [Gy] 44.8 46.2 (103.1%) 44.7 (99.8%) 45.6 (101.8%)
D1% [%] - 110.3 110.7 106.5
D99% [%] - 96.0 90.6 94.0
V90% [%] 100% 99.9 99.4 99.9
V95% [%] 100% 99.5 88.3 98.4
V107% [%] 0% 5.3 3.0 0.3
V110% [%] 0% 1.2 1.2 0.0
D5–D95 [%] - 7.1 12.3 7.8
SD [%] - 2.5 4.0 2.5
Vertebra
Mean [Gy] < 20 Gy 17.6 13.6 22.2
D1% [Gy] Minim 51.5 53.8 52.5
Spinal Cord
D1% [Gy] < 45 Gy 15.8 15.2 16.9
Right Lung
Mean [Gy] < 15 Gy 11.9 0.9 11.9
V20 Gy [%] Minim 8.8 0.3 11.4
Left uninvolved Lung
Mean [Gy] < 15 Gy 14.1 6.4 15.5
V20 Gy [%] Minim 20.0 11.8 25.1
Heart
Mean [Gy] < 30 Gy 29.1 3.8 26.7
V40 Gy [%] Minim 11.9 3.2 10.1
D1% [Gy] Minim 53.1 51.9 50.0
Healthy tissue
Mean [Gy] Minim 9.1 2.5 8.7
V10 Gy [cm3] Minim 32.2 7.2 31.0
EI [%] Minim 3.0 3.5 2.9
DosInt [105 *Gy*cm3] Minim 0.84 0.23 0.81Radiation Oncology 2009, 4:2 http://www.ro-journal.com/content/4/1/2
Page 14 of 19
(page number not for citation purposes)
Patient 4
The main challenge in this case was to minimize the expo-
sure of organs at risk located inside the triangle formed by
the three disconnected targets. Nevertheless all the tech-
niques were able to largely improve the planning objec-
tives. Concerning uterus both HT and RA attested mean
dose below 10 Gy, more than a factor 2 below the con-
straint. Similarly for the Rectum (< 20 Gy for both RA and
HT against an objective of 40 Gy), for the bladder (with a
reduction of a factor ~2 for RA and ~1.7 for HT), and for
the femurs. RA plans were generally better than HT for the
bladder (below 20 Gy), equivalent to HT for the rectum
and the uterus, and inferior to HT for the femurs. For this
patient, IMP granted the most significant sparing of OARs
compared to the photon techniques. The mean dose was
Table 3: Results from dose plan analysis for Patient 2
Obj. HT IMP RA
PTVII
Mean [Gy] 49.5 49.5
(100%)
49.5
(100%)
49.5
(100%)
D1% [%] - 103.2 103.8 103.4
D99% [%] - 93.3 94.7 92.7
V90% [%] 100% 99.9 100.0 99.8
V95% [%] 100% 97.5 98.7 96.2
V107% [%] 0% 0.0 0.0 0.0
V110% [%] 0% 0.0 0.0 0.0
D5–D95 [%] - 6.5 5.9 7.3
SD [%] - 1.8 1.8 2.2
CI90 1.0 1.1 1.1 1.0
PTVI-PTVII
Mean [%] 45.0 47.0
(104.4%)
47.6
(105.8%)
46.7
(103.8%)
D1% [%] - 112.9 113.1 111.3
D99% [%] - 92.9 95.3 91.1
V90% [%] 100% 99.7 99.9 99.3
V95% [%] 100% 98.1 99.2 95.4
V107% [%] 0% 31.2 45.6 28.3
V110% [%] 0% 11.6 6.7 6.3
D5–D95 [%] - 13.8 11.6 15.1
SD [%] - 4.4 3.6 4.7
Vertebra
Mean [Gy] < 20 Gy 10.5 4.3 10.5
D1% [Gy] < 45 Gy 25.8 37.2 34.8
Spinal Cord
D1% [Gy] < 45 Gy 11.0 1.4 10.1
Right Lung
Mean [Gy] < 15 Gy 9.1 3.6 7.7
V5 Gy [%] Minim 47.7 16.5 43.7
V20 Gy [%] Minim 14.8 6.9 13.6
Left Lung
Mean [Gy] < 15 Gy 13.2 7.0 12.0
V5 Gy [%] Minim 63.7 30.9 54.0
V20 Gy [%] Minim 27.0 14.0 26.4
Heart
Mean [Gy] < 30 Gy 6.5 2.4 2.3
V20 Gy [%] Minim 13.2 5.0 2.7
D1% [Gy] Minim 42.1 38.0 31.1
Healthy tissue
Mean Gy] Minim 5.0 1.7 4.0
V10 Gy [cm3] Minim 18.9 5.4 8.9
EI [%] Minim 0.0 0.1 0.0
DosInt [105 *Gy*cm3] Minim 0.29 0.10 0.23
Table 4: Results from dose plan analysis for Patient 3
Obj. HT IMP RA
PTVII
Mean [Gy] 42.5 42.5
(100%)
42.5
(100%)
42.5
(100%)
D1% [%] - 102.4 106.1 103.5
D99% [%] - 94.8 83.8 94.1
V90% [%] 100% 100.0 97.9 100.0
V95% [%] 100% 98.9 95.6 100.0
V107% [%] 0% 0.0 0.5 0.
V110% [%] 0% 0. 0. 0.
D5–D95 [%] - 4.0 8.2 6.1
SD [%] - 1.2 3.8 1.9
CI90 1.0 1.0 1.0 1.2
PTVI-PTVII
Mean [Gy] 30.6 31.3
(102.3%)
31.3
(102.3%)
31.5
(102.9%)
D1% [%] - 126.5 122.4 130.4
D99% [%] - 89.9 95.8 94.8
V90% [%] 100% 98.9 99.6 100.
V95% [%] 100% 96.7 99.2 100.
V107% [%] 0% 9.7 6.6 8.3
V110% [%] 0% 5.4 2.9 5.2
D5–D95 [%] - 13.4 9.5 14.0
SD [%] - 5.2 4.6 5.6
Spinal Cord
D1% [Gy] < 45 Gy 31.8 29.4 32.3
Right Eye
Mean [Gy] < 15 Gy 15.3 12.2 12.3
V20 Gy [%] Minim 29.2 24.3 15.3
D1% [Gy] Minim 36.8 34.6 30.5
Right Lens
Mean [Gy] < 15 Gy 11.8 1.9 7.9
D1% [Gy] Minim 18.4 2.7 10.2
Healthy tissue
Mean Gy] Minim 17.3 14.2 15.7
V10 Gy [cm3] Minim 74.3 56.9 62.7
EI [%] Minim 0.1 0.1 0.0
DosInt [105 *Gy*cm3] Minim 0.25 0.20 0.23Radiation Oncology 2009, 4:2 http://www.ro-journal.com/content/4/1/2
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about 10 times lower for the right and about 50 times
lower for the left femurs; about 20 times lower for the
uterus; about 4 times for the bladder and slightly less than
a factor of 2 for the rectum.
Patient 5
For this patient, the primary planning objective was to
protect the kidney and all techniques largely succeeded:
HT and RA showed equivalent results (also visible from
the DVH graphs) and IMP reduced of a factor about 5 the
mean dose to this organ. RA resulted in a better sparing of
the stomach and lungs although these organs were not
explicitly considered in the optimisation phase and there-
fore no special effort was put in their sparing.
Healthy tissue sparing
From table 7, IMP resulted systematically and significantly
better than either RA or HT as expected reducing of a fac-
tor 2 the dose integral, the mean dose, and V10 Gy. Never-
theless, IMP showed a tendency to spill more dose outside
the target volumes resulting in a higher External Index
although inferior to 2.5%. It is important to notice the dif-
ference in V10 Gy between RA and HT (about 23% higher
with HT), systematic effect due to the inherent wider dose
Table 5: Results from dose plan analysis for Patient 4
Obj HT IMP RA
PTVII
Mean [Gy] 49.5 49.5
(100%)
49.5
(100%)
49.5
(100%)
D1% [%] - 106.9 106.5 103.2
D99% [%] - 94.1 89.9 93.7
V90% [%] 100% 99.9 98.9 99.8
V95% [%] 100% 98.6 93.9 98.2
V107% [%] 0% 0.9 0.7 0.0
V110% [%] 0% 0 0 0
SD [Gy] - 2.2 3.2 1.8
D5–D95 [Gy] - 7.3 9.9 5.3
CI90 1.0 2.3 1.3 1.7
PTVI (left and right)
Mean [Gy] 45 44.6
(99.1%)
44.6
(99.1%)
45.0
(100%)
D1% [%] - 102.7 110.0 103.8
D99% [%] - 94.0 85.6 94.4
V90% [%] 100% 99.8 96.8 99.9
V95% [%] 100% 98.5 87.5 99.0
V107% [%] 0% 0 0 6.2 0 0
V110% [%] 0% 0 0 1.4 0 0
D5–D95 [%] - 4.0 13.6 5.6
SD [%] - 1.6 4.2 1.8
Uterus
Mean [Gy] < 20 Gy 9.0 0.5 8.8
D1% [Gy] Minim 11.4 4.4 10.7
V10 Gy [%] Minim 12.4 0.0 4.4
Rectum
Mean [Gy] < 40 Gy 18.4 10.6 19.3
D1% [Gy] Minim 52.2 51.0 49.9
V40 Gy [%] Minim 12.4 11.8 15.4
Bladder
Mean [Gy] < 30 Gy 17.8 4.3 15.5
D1% [Gy] Minim 34.3 35.0 33.0
V20 Gy [%] Minim 21.0 6.5 19.2
Right Femur
Mean [Gy] < 20 Gy 14.4 1.5 18.8
D1% [Gy] Minim 38.4 28.2 41.0
Left Femur
Mean [Gy] < 20 Gy 14,3 0.3 18.2
D1% [Gy] Minim 37.2 10.8 37.7
Healthy tissue
Mean Gy] Minim 13.8 3.7 12.2
V10 Gy [cm3] Minim 51.2 11.8 42.9
EI [%] Minim 4.1 5.0 3.3
DosInt [105 *Gy*cm3] Minim 1.1 0.3 1.0
Table 6: Results from dose plan analysis for Patient 5
Obj HT IMP RA
PTV
Mean [Gy] 18.0 18.0
(100%)
18.0
(100%)
18.0
(100%)
D1% [% - 117.2 109.4 107.8
D99% [%] - 79.4 72.2 86.7
V90% [%] 100% 97.1 96.1 98.1
V95% [%] 100% 94.6 92.5 91.3
V107% [%] 0% 4.7 2.5 1.8
V110% [%] 0% 3.0 0.7 0.3
D5–D95 [%] - 12.2 13.3 11.7
SD [%] - 5.6 6.1 4.4
CI90 1.0 1.15 1.12 1.12
Kidney
Mean [Gy] < 10 Gy 4.0 0.8 3.5
D1% [Gy] Minim 10.8 7.4 10.9
D30% [Gy] Minim 4.1 0.2 3.5
V5 Gy [%] Minim 22.0 4.6 18.4
Stomach – PTV
Mean [Gy] Minim 12.4 2.9 11.2
D1% [Gy] Minim 17.4 13,8 17.8
D30% [Gy] Minim 14.5 3.6 13.3
V15 Gy [%] Minim 24.3 0.4 16.7
Healthy tissue
Mean [Gy] Minim 7.1 2.6 6.0
V10 Gy [%] Minim 30.8 12.6 23.3
EI [%] Minim 0.8 2.6 0.8
DosInt [105 *Gy*cm3] Minim 2.77 1.03 2.36Radiation Oncology 2009, 4:2 http://www.ro-journal.com/content/4/1/2
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penumbra in the cranial and caudal directions of HT. On
a patient per patient basis and limiting to the two photon
techniques (IMP being obviously the best), no differences
from the DVH graphs can be observed between RA and HT
for patient 1. For patient 2, RA granted slightly better spar-
ing below 15 Gy if compared to HT. Similarly for patient
3, 4, and 5, RA additionally spared healthy tissue below
20 Gy.
Delivery time
Beam-on times for RA and HT reported in table 1 range
from 123 to 129 s for RA, average: 127.5 s (two arcs for
each plan) and from 146 to 387 s for HT (average 292.6
seconds). The rather uniform time distribution of RA
compared to the larger variation of HT is mostly due to the
volumetric vs helicoidal delivery methods implying for
HT a delivery time proportional to the target length (and
inversely proportional to the pitch factor) while for RA
there is an obvious independence from the target length.
Discussion and conclusion
This study aimed to address the effectiveness of advanced
radiation treatment techniques for selected challenging
paediatric scenarios. The study compared Helical Tomo-
therapy, RapidArc and Intensity Modulated Protons. Each
case was selected as paradigmatic of some planning chal-
lenge by virtue of the target to be treated and the sur-
rounding anatomy/proximity of organs at risk and the
study did not aimed to answer to a specific clinical issue
but rather to investigate some dosimetric features of dif-
ferent techniques in a variety of conditions. All techniques
sufficiently respected conformation and avoidance objec-
tives and generated clinically acceptable plans. As
expected, protons presented a significant improvement in
OAR sparing at the price of a slightly compromised cover-
age of targets. This negative effect could be quite easily
compensated by increasing, at planning level, the lateral,
caudal and distal margins in the spot list creation and
optimisation. In the present study the margins were set to
rather tight values (between 2 and 5 mm), wider margins
would impact on the sparing of OARs, on Conformity
Index and External volume Index, but the space for advan-
tageous trade-off is likely significant and the parameters
adopted in the study do not affect the general conclusion
about substantial superiority of protons. Nevertheless,
since access to proton facilities is still relatively limited in
the world and therefore, many paediatric patients will
need photon based radiotherapy, it is of interest to
explore advanced photon techniques. Restricting the dis-
cussion to HT and RA, it is possible to state that: i) both
approaches are satisfactory and qualitatively comparable
in terms of conformal avoidance; ii) as a consequence
Table 7: Average results over the five patients from dose plan analysis on target volumes and healthy tissue.
Obj HT IMP RA
PTVII
D1% [%] - 106.4 ± 6.3 106.6 ± 2.0 104.6 ± 1.9
D99% [%] - 89.3 ± 6.8 85.5 ± 8.5 91.6 ± 3.0
V90% [%] 100% 98.9 ± 1.4 98.1 ± 1.5 99.4 ± 0.8
V95% [%] 100% 96.7 ± 2.3 94.8 ± 2.4 95.6 ± 3.7
V107% [%] 0% 1.1 ± 2.0 1.0 ± 0.9 0.4 ± 0.8
V110% [%] 0% 0.6 ± 1.3 0.2 ± 0.3 0.1 ± 0.1
SD [Gy] - 3.8 ± 2.6 5.0 ± 3.1 3.4 ± 1.5
D5–D95 [Gy] - 6.6 ± 3.7 8.3 ± 4.0 7.4 ± 3.8
CI90 1.0 1.3 ± 0.5 1.1 ± 0.1 1.2 ± 0.3
PTVI-PTVII
D1% [%] - 113.1 ± 9.9 114.1 ± 5.7 113.0 ± 12.0
D99% [%] - 93.2 ± 2.6 91.8 ± 4.8 93.6 ± 1.7
V90% [%] 100% 99.6 ± 0.5 98.9 ± 1.4 99.8 ± 0.3
V95% [%] 100% 98.2 ± 1.2 93.6 ± 6.5 98.2 ± 2.0
V107% [%] 0% 15.4 ± 13.9 15.4 ± 20.2 12.3 ± 14.4
V110% [%] 0% 6.1 ± 5.2 3.1 ± 2.6 3.8 ± 3.4
D5–D95 [%] - 9.6 ± 4.8 11.8 ± 1.7 10.6 ± 4.6
SD [%] - 3.4 ± 1.7 4.1 ± 0.4 3.7 ± 1.8
Healthy tissue
Mean Gy] Minim 10.5 ± 5.0 4.9 ± 5.2 9.3 ± 4.7
V10 Gy [cm3] Minim 41.5 ± 21.7 18.8 ± 21.5 33.8 ± 20.3
EI [%] Minim 1.6 ± 1.8 2.3 ± 2.2 1.4 ± 1.6
DosInt [105 *Gy*cm3] Minim 1.1 ± 1.0 0.4 ± 0.4 0.9 ± 0.9Radiation Oncology 2009, 4:2 http://www.ro-journal.com/content/4/1/2
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there is no evidence to prefer one solution over the other
on a dosimetric base. That said, differences do exist
between the two photon techniques. In first instance, HT
dose distributions showed a systematically broadening of
doses in the caudal and cranial directions compared to
RA. This is due to the fact that HT plans were optimised
using a field size (i.e. the width of the helicoidal slice) of
2.5 cm (at the time of the study, the 1.0 cm beam was not
commissioned for the tomotherapy unit in London). In
principle, a tighter conformation of doses along the cra-
nial-caudal axis would have been possible using a field
size of 1.0 cm but at the price of a significantly prolonged
treatment time (this scales roughly inversely proportional
to the field size). With the configuration used in this study
the beam-on time for HT is 2.2 times longer than for RA.
The clinical relevance of beam-on time is hard to quantify
and is beyond the scope of this study but can impact on
patient's comfort, stability of positioning and internal
organs movement. In addition for very young patients
requiring anaesthesia for treatment, shorter treatment
times may be desirable to decrease the length of sedation
(or in some cases perhaps avoid sedation).
The present study incorporated some assumptions or lim-
its that shall be disclosed. A first issue might concern inter-
nal organs motion due to respiration, in principle
important in patients 1, 2 and 5. All the techniques inves-
tigated here, do not currently allow for motion compensa-
tion through either gating or tumour tracking. This, up to
now, has to accounted for with larger margins to targets.
In any case, focussing on paediatric treatment, any solu-
tion that will arrive in the future will have to be carefully
considered if longer treatment time will be needed to treat
the patient (as it is for example with gating solutions). On
the other side, studies proved that with photons, irradia-
tion can be improved [31] if breathing control is applied,
the same authors suggested that mid-ventilation phase
could be an adequate surrogate of breath control since,
statistically, it is the phase where targets can be "seen" by
static beams for the longest time provided adequate mar-
gins are defined. In the present study, the CT dataset used
can be considered as average mid-ventilation phase par-
tially solving the issue. A recent investigation [32] proved
also the principle feasibility of target tracking in combina-
tion with RA delivery. It is therefore possible to conclude
that, in absence of advanced methods, mid-ventilation
could be applied as a first degree approach waiting for the
clinical implementation of tracking.
A second consideration is linked to the use of two arcs,
some of them non co-planar, for the RA plans. Undoubt-
edly, the application of two arcs was necessary to achieve
the high degree of conformal avoidance required by the
planning objectives, also non co-planarity was introduced
to improve results. Data for single arcs are not presented
for simplicity. Since in the paediatric treatments, greatest
care should be given to OARs sparing, the usage of multi-
ple arcs offered a significant improvement and therefore
was considered important. The option for the use of non-
coplanar arcs is another difference between HT (which is
coplanar in delivery) and RA and may offer advantages in
some anatomic sub-sites [33].
Some limitations of the present study concern organs at
risk not explicitly considered in the analysis. In particular:
immature breasts for patient 2 or ovaries for patient 4 and
were already addressed in the discussion of the previous
publication [2]. Breast for patient 2: in this case the issue
is not the involvement of the glands at high dose levels
but rather the dose bath and the potential for secondary
cancer induction. In the absence of reliable models to pre-
dict the risk of secondary cancers it would be mostly spec-
ulative to provide data pointing at this endpoint.
Moreover there are no values in literature that can reliably
be used as tolerance dose levels for breast irradiation (as
an organ) in children. The breasts were anyway included
in our analysis as part of the healthy tissue (instead of con-
sidering them as specific organs). For protons, a dorsal
approach might have been eventually beneficial but, also
with the geometry used in this study, the mean dose to the
immature glands is anyway inferior to 5 Gy (being the
glands mostly outside the field, figure 2) and therefore
respecting tolerances often used for adults. Ovaries for
patient 3: this is an even more delicate case since dose tol-
erance (in the range of 4–12 Gy) changes, decreasing with
age. Ovaries were not included in the study because of
their insufficient detection on the CT dataset. Given that
the tolerance level is very low with respect to the pre-
scribed dose (50.4 Gy), the impossibility to have a correct
location of the organs, and their close proximity to the tar-
get, a proper sparing these organs would be unreliable and
compromising too severely the target coverage. We
recorded the dose to the 'ovarian region' resulting from
the plans and it was around 20–30 Gy for photon tech-
niques.
A final important point relates to the analysis of the
healthy tissue involvement. Assuming the need to reduce
maximally the amount of healthy tissue irradiated at any
dose level, HT and RA was associated with significantly
larger low dose volumes. This crucial difference is corre-
lated directly to the risk of secondary cancer induction
and, although no specific modelling was applied to the
data, it is obvious, from the Hall [18,19], Cozzi [23], Ram-
sey [34] data on peripheral dose that, whenever possible,
paediatric patients should be treated with IMP (spot scan-
ning, not passive scattered). Beside the already addressed
differences at the cranial-caudal edges of the target, HT
and RA did not showed different patterns of healthy tissue
irradiation and therefore can be associated with similarRadiation Oncology 2009, 4:2 http://www.ro-journal.com/content/4/1/2
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risks. Others have reported on comparisons of HT to other
photon IMRT and demonstrated lower scattered dose
[32]; as well, RA has been reported to be associated with
lower scattered dose than other photon IMRT in [23]. This
last point, together with the possibility of not increasing
the risk for secondary cancers if technologies presenting a
higher dose bath with respect to conformal treatment
[20], proves the importance of considering such a modern
techniques for children who need a radiation treatment.
In any case the clear minimal amount of low/medium
dose level deliverable with protons is not reachable with
photons, confirming the superiority of protons in terms of
low dose spread. The integral dose to healthy tissue
reported in table 7 as average over the five patients shows
that this value for IMP is less than halved relatively to pho-
ton deliveries, and, in this respect, RA could result in
slightly lower values than HT,
A remark on the choice of RA as a comparing technique
used in the present work has to be clarified: this is one of
the recently developed techniques based on linac, in the
wider frame of the volumetric intensity modulated arc
therapy. Other commercial solutions are becoming avail-
able nowadays. The results here shown, as they are, are
clearly specific to RA, but similar general ideas could be
eventually drawn also for the other intensity modulated
arc solutions.
To conclude, the three techniques under investigation
generated very similar plans for all the targets and no sig-
nificant negative effect was observed in simultaneously
optimising multiple dose levels. In particular the dose dis-
tributions of the differential targets (PTVII-PTVI) proved
to be sharp with minimal tails (confirmed by relatively
low findings on corresponding V110%). This fact is a guar-
antee of the high modulation and high dose gradient
capabilities and precise conformation to dose prescription
of three completely different optimisation approaches,
volumetric (RA), helicoidal (HT) and voxelised (IMP).
All three methods are nicely adequate to generate very
complex dose patterns and seem appropriate for further
investigation in the context of clinical trials of advanced
radiotherapy techniques for paediatric cancers.
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